Pfizer CEO Albert Bourla said a key safety milestone had been reached at clinical trial of its vaccine against Covid-19.
At an organized conference Tuesday by the New York Times, Bourla said that the company was preparing to submit its data to US Food and Drug Administration. (FDA) to request an emergency use authorization.
Last week, the company and its partner, BioNTech SE, reported that an interim analysis showed that their vaccine was more than 90% effective in preventing Covid-19.
“We are preparing for the presentations”Bourla said at the DealBook conference.
Bourla has said that the company can produce up to 50 million doses by the end of the year, and half of that supply will go to other countries. Because the vaccine requires two doses, there will initially be enough for only 12.5 million of the 330 million Americans.